Expert analysis of institutional factors hindering drug price reduction
Experts pointed out that to properly adjust the drug price of enterprises, it is necessary to reduce the burden from policy, transform the system, create a good external environment of low-cost products for enterprises, and let the company have the enthusiasm and initiative to reduce the drug price, so as to fully mobilize the resources of the whole society, work together to reduce the medical burden for the people, and truly benefit the people's well-being.
At present, the factors that prevent the decline of drug prices still exist in essence, and to a certain extent, they seriously affect the pace of medical reform, increase the burden of the people, and prevent the company from carrying out a diversified layout of the shopping mall strategy. These elements are mainly as follows: first, if all companies in the country adopt the strategy of lowest quotation for linkage, many companies will not be able to bear this cost, and can only be abandoned after all. The economic development of China's provinces, cities and autonomous regions is not the same, the corresponding level of medical management and medical production are not the same, and the purchasing power of people to quote the same medicine is not the same, but today's policy requires the same price of the same medicine, and many people in poor areas can only abandon it. According to the actual economic development level of various provinces and cities, we should give enterprises more independence in drug pricing, and no longer adopt a one size fits all attitude. Second, using the lowest supply price as the basis for acquisition has violated the industry law. Because of the different situation of each hospital, the right of independent pricing of the company has been elevated, and the market is profit-making in essence, which forces some companies to abandon the drug market with low price and not launch low-priced drugs.
Policy support provides a healthy development environment for the pharmaceutical industry. Bidding can only be regarded as the most basic measure for hospitals to purchase drugs. The final pricing of retail drugs depends on the decision of the enterprise itself, so excessive intervention in the industry market should be reduced, which can help the enterprise to fully demonstrate creativity and subjective initiative and highlight the "invisible hand" Control effect.